Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNYSE:BHVNNASDAQ:ORKANASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Companies$4.60+1.1%$5.10$3.96▼$9.85$1.68B0.342.55 million shs1.17 million shsBHVNBiohaven$14.70-2.4%$19.86$14.50▼$55.70$1.50B1.181.22 million shs3.03 million shsORKAOruka Therapeutics$11.85+3.3%$9.74$5.49▼$31.13$443.68M0.25224,637 shs128,700 shsSDGRSchrödinger$21.44-0.4%$22.70$16.60▼$28.47$1.57B1.84865,067 shs759,424 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Companies+1.05%+2.18%-16.40%-38.16%-25.05%BHVNBiohaven-2.30%-4.89%-32.83%-60.36%-55.88%ORKAOruka Therapeutics+3.31%+5.90%+13.40%+16.75%+1,184,999,900.00%SDGRSchrödinger-0.37%+1.04%-16.83%-3.90%+0.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Companies4.4607 of 5 stars2.95.00.04.02.31.71.9BHVNBiohaven3.3946 of 5 stars4.51.00.00.02.04.20.6ORKAOruka Therapeutics2.8677 of 5 stars3.60.00.00.03.52.50.6SDGRSchrödinger2.2667 of 5 stars3.51.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Companies 1.86Reduce$7.4261.30% UpsideBHVNBiohaven 3.07Buy$59.46304.39% UpsideORKAOruka Therapeutics 3.20Buy$40.38240.72% UpsideSDGRSchrödinger 3.00Buy$32.8052.99% UpsideCurrent Analyst Ratings BreakdownLatest ORKA, BHC, BHVN, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$44.005/19/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/15/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/2/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.50(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Companies$9.73B0.17$4.89 per share0.94($0.89) per share-5.17BHVNBiohavenN/AN/AN/AN/A$5.34 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/AN/ASDGRSchrödinger$230.49M6.83$0.57 per share37.42$7.60 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Companies-$46M-$0.11N/A0.990.37-0.48%-577.82%5.24%7/30/2025 (Estimated)BHVNBiohaven-$408.17M-$9.36N/AN/AN/AN/A-225.12%-158.89%8/14/2025 (Estimated)ORKAOruka Therapeutics-$5.34M-$4.51N/AN/AN/AN/A-24.96%-21.22%8/7/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)Latest ORKA, BHC, BHVN, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million3/6/2025Q4 2024ORKAOruka Therapeutics-$0.68-$0.49+$0.19-$0.49N/AN/A3/3/2025Q4 2024BHVNBiohaven-$1.56-$1.85-$0.29-$1.85$100.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CompaniesN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CompaniesN/A0.860.62BHVNBiohavenN/A2.892.89ORKAOruka TherapeuticsN/A22.8922.89SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Companies78.65%BHVNBiohaven88.78%ORKAOruka Therapeutics56.44%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Companies8.05%BHVNBiohaven16.00%ORKAOruka Therapeutics22.67%SDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Companies19,900364.40 million338.06 millionOptionableBHVNBiohaven239102.11 million84.94 millionOptionableORKAOruka TherapeuticsN/A37.44 million27.07 millionN/ASDGRSchrödinger79073.38 million66.59 millionOptionableORKA, BHC, BHVN, and SDGR HeadlinesRecent News About These CompaniesVoloridge Investment Management LLC Cuts Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 30 at 4:02 AM | marketbeat.comAmeriprise Financial Inc. Has $2.67 Million Position in Schrödinger, Inc. (NASDAQ:SDGR)May 30 at 3:05 AM | marketbeat.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerMay 29 at 9:51 PM | finance.yahoo.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial OfficerMay 29 at 6:03 PM | businesswire.comSchrdinger, Inc. (SDGR) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky TodayMay 29 at 10:20 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to ConnectMay 29 at 10:00 AM | accessnewswire.comOngoing Schrdinger, Inc. (SDGR) Investigation: Protect Your Rights - Contact Levi & KorsinskyMay 28 at 2:15 PM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities InvestigationMay 28 at 10:00 AM | accessnewswire.comIntegrated Advisors Network LLC Sells 17,547 Shares of Schrödinger, Inc. (NASDAQ:SDGR)May 28 at 5:52 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $31.25 Million Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)May 28 at 4:48 AM | marketbeat.comBNP Paribas Financial Markets Makes New Investment in Schrödinger, Inc. (NASDAQ:SDGR)May 28 at 3:16 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRMay 27 at 12:00 PM | accessnewswire.comRXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?May 27 at 11:01 AM | zacks.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach OutMay 27 at 10:00 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to ConnectMay 26, 2025 | accessnewswire.comSchrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationMay 25, 2025 | accessnewswire.comMillennium Management LLC Raises Position in Schrödinger, Inc. (NASDAQ:SDGR)May 25, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRMay 24, 2025 | accessnewswire.comCaptrust Financial Advisors Takes $240,000 Position in Schrödinger, Inc. (NASDAQ:SDGR)May 24, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the InvestigationMay 23, 2025 | accessnewswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 23, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORKA, BHC, BHVN, and SDGR Company DescriptionsBausch Health Companies NYSE:BHC$4.60 +0.05 (+1.05%) Closing price 05/29/2025 03:59 PM EasternExtended Trading$4.61 +0.01 (+0.15%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Biohaven NYSE:BHVN$14.70 -0.36 (-2.36%) Closing price 05/29/2025 03:59 PM EasternExtended Trading$15.03 +0.32 (+2.19%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Oruka Therapeutics NASDAQ:ORKA$11.85 +0.38 (+3.31%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$11.87 +0.02 (+0.14%) As of 05/29/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Schrödinger NASDAQ:SDGR$21.44 -0.08 (-0.37%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$21.40 -0.04 (-0.19%) As of 05:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
